Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multiple-dose study of ezogabine/retigabine in adolescents with seizures
2012-001132-60Phase 2
- Sponsor
- GSK
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retigabine in Focal onset seizure, Lennox-Gastaut syndrome (LGS) and epilepsy, sponsored by GSK. Primary endpoint: Steady-state pharmacokinetics of ezogabine/retigabine.
02
Drugs
retigabine
03
Conditions
Focal onset seizureLennox-Gastaut syndrome (LGS)epilepsy
Beyond the preview
Go deeper on 2012-001132-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001132-60.